(Q57578316)

1

0 references

Kathleen M. Mahoney

2

0 references

Patrick G. Morris

3

0 references

Sujata Patil

4

0 references

Lindsay M. Jacks

5

0 references

Jane Howard

6

0 references

Clifford A. Hudis

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

8

0 references

language of work or name

English

0 references

publication date

16 June 2011

0 references

published in

Cancer

0 references

volume

117

0 references

issue

24

0 references

page(s)

5461-5468

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171

inferred from DOI database lookup

7 January 2021

based on heuristic

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26171